Yale Catriona 4
4 · Akero Therapeutics, Inc. · Filed Jul 18, 2025
Insider Transaction Report
Form 4
Yale Catriona
Chief Development Officer
Transactions
- Sale
Common Stock
2025-07-16$52.87/sh−8,658$457,705→ 92,830 total - Exercise/Conversion
Common Stock
2025-07-16$19.87/sh+10,000$198,700→ 101,488 total - Sale
Common Stock
2025-07-16$53.47/sh−1,342$71,762→ 91,488 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-07-16−10,000→ 131,205 totalExercise: $19.87Exp: 2033-12-07→ Common Stock (141,205 underlying)
Footnotes (4)
- [F1]The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 24, 2024, previously adopted by the Reporting Person.
- [F2]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $52.34 to $53.31, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $53.35 to $53.58, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F4]The options are vested and currently exercisable.